Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review...

por Kuendgen, Andrea, Müller-Thomas, Catharina, Lauseker, Michael, Haferlach, Torsten, Urbaniak, Petra, Schroeder, Thomas, Brings, Carolin, Wulfert, Michael, Meggendorfer, Manja, Hildebrandt, Barbara, Betz, Beate, Royer-Pokora, Brigitte, Gattermann, Norbert, Haas, Rainer, Germing, Ulrich, Götze, Katharina S.
Publicado 2018

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

por Reidel, Veronika, Kauschinger, Johanna, Hauch, Richard T., Müller-Thomas, Catharina, Nadarajah, Niroshan, Burgkart, Rainer, Schmidt, Burkhard, Hempel, Dirk, Jacob, Anne, Slotta-Huspenina, Julia, Höckendorf, Ulrike, Peschel, Christian, Kern, Wolfgang, Haferlach, Torsten, Götze, Katharina S., Jilg, Stefanie, Jost, Philipp J.
Publicado 2018

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

por Jilg, Stefanie, Hauch, Richard T., Kauschinger, Johanna, Buschhorn, Lars, Odinius, Timo O., Dill, Veronika, Müller-Thomas, Catharina, Herold, Tobias, Prodinger, Peter M., Schmidt, Burkhard, Hempel, Dirk, Bassermann, Florian, Peschel, Christian, Götze, Katharina S., Höckendorf, Ulrike, Haferlach, Torsten, Jost, Philipp J.
Publicado 2019